Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Yu SS, Ortega RA, Reagan BW, McPherson JA, Sung HJ, Giorgio TD
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 3 (6): 620-46

PMID: 21834059 · PMCID: PMC5486233 · DOI:10.1002/wnan.158

An estimated 16 million people in the United States have coronary artery disease (CAD), and approximately 325,000 people die annually from cardiac arrest. About two-thirds of unexpected cardiac deaths occur without prior recognition of cardiac disease. A vast majority of these deaths are attributable to the rupture of 'vulnerable atherosclerotic plaques'. Clinically, plaque vulnerability is typically assessed through imaging techniques, and ruptured plaques leading to acute myocardial infarction are treated through angioplasty or stenting. Despite significant advances, it is clear that current imaging methods are insufficiently capable for elucidating plaque composition--which is a key determinant of vulnerability. Further, the exciting improvement in the treatment of CAD afforded by stenting procedures has been buffered by significant undesirable host-implant effects, including restenosis and late thrombosis. Nanotechnology has led to some potential solutions to these problems by yielding constructs that interface with plaque cellular components at an unprecedented size scale. By leveraging the innate ability of macrophages to phagocytose nanoparticles, contrast agents can now be targeted to plaque inflammatory activity. Improvements in nano-patterning procedures have now led to increased ability to regenerate tissue isotropy directly on stents, enabling gradual regeneration of normal, physiologic vascular structures. Advancements in immunoassay technologies promise lower costs for biomarker measurements, and in the near future, may enable the addition of routine blood testing to the clinician's toolbox--decreasing the costs of atherosclerosis-related medical care. These are merely three examples among many stories of how nanotechnology continues to promise advances in the diagnosis and treatment of vulnerable atherosclerotic plaques.

Copyright © 2011 John Wiley & Sons, Inc.

MeSH Terms (5)

Coronary Artery Disease Humans Nanomedicine Nanostructures Plaque, Atherosclerotic

Connections (3)

This publication is referenced by other Labnodes entities: